Fundamental Data for SGMO

SANGAMO BI(NSDQ:SGMO)

Sangamo BioSciences, Inc. is a leader in the development of noveltranscription factors for the regulation of gene expression. Transcriptionfactors are proteins that turn genes on or off by recognizing specific DNAsequences. The Universal Gene Recognition technology platform enables theengineering of a class of transcription factors known as zinc finger DNA binding proteins.

# Employees: 77

Address: 501 Canal Boulevard Suite A100,Richmond,CA,USA

Phone: 510 970-6000

Fax: 510 236-8951

Website: www.sangamo.com

Email: investor.relations@Sangamo.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Edward O. Lanphier II (Pres.; C.E.O.; Dir.)

Ward H. Wolff (Exec. V.P.; C.F.O.)

William G. Gerber M.D. (Dir.)

John W. Larson (Dir.)

Margaret A. Liu M.D. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/10/2010

Mean EPS (Next Qtr): ($0.09)

Mean EPS (Year): ($0.47)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 8

Shares Performance

Period	SGMO	Compare to S&P
YTD	58.33 %	31.04 %
4 Weeks	-8.47 %	-9.46 %
12 Weeks	-22.17 %	-26.63 %

Shares Information

Analyst Coverage: Y

Avg Volume: 322238

Shares Outstanding: 41M

Market Cap: $0.23B

52 Week High: $9.03

52 Week Low: $2.02

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 6/7/1981 SGMO split by factor of 1.250

Earnings Performance

EPS Growth in Last Quarter: -9.09 %

EPS Growth in Last Year: 20.00 %

Sales Growth in Last Quarter: -14.03 %

Sales Growth in Last Quarter: 8.49 %

Financials

Qtr Book Value: $5.10

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 12.080